Leveraging machine learning for predicting acute graft-versus-host disease grades in allogeneic hematopoietic cell transplantation for T-cell prolymphocytic leukaemia.


Journal

BMC medical research methodology
ISSN: 1471-2288
Titre abrégé: BMC Med Res Methodol
Pays: England
ID NLM: 100968545

Informations de publication

Date de publication:
11 May 2024
Historique:
received: 14 01 2024
accepted: 02 05 2024
medline: 12 5 2024
pubmed: 12 5 2024
entrez: 11 5 2024
Statut: epublish

Résumé

Orphan diseases, exemplified by T-cell prolymphocytic leukemia, present inherent challenges due to limited data availability and complexities in effective care. This study delves into harnessing the potential of machine learning to enhance care strategies for orphan diseases, specifically focusing on allogeneic hematopoietic cell transplantation (allo-HCT) in T-cell prolymphocytic leukemia. The investigation evaluates how varying numbers of variables impact model performance, considering the rarity of the disease. Utilizing data from the Center for International Blood and Marrow Transplant Research, the study scrutinizes outcomes following allo-HCT for T-cell prolymphocytic leukemia. Diverse machine learning models were developed to forecast acute graft-versus-host disease (aGvHD) occurrence and its distinct grades post-allo-HCT. Assessment of model performance relied on balanced accuracy, F1 score, and ROC AUC metrics. The findings highlight the Linear Discriminant Analysis (LDA) classifier achieving the highest testing balanced accuracy of 0.58 in predicting aGvHD. However, challenges arose in its performance during multi-class classification tasks. While affirming the potential of machine learning in enhancing care for orphan diseases, the study underscores the impact of limited data and disease rarity on model performance.

Identifiants

pubmed: 38734644
doi: 10.1186/s12874-024-02237-y
pii: 10.1186/s12874-024-02237-y
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

112

Informations de copyright

© 2024. The Author(s).

Références

Arai Y, Kondo T, Fuse K, Shibasaki Y, Masuko M, Sugita J, et al. Using a machine learning algorithm to predict acute graft-versus-host disease following allogeneic transplantation. Blood Adv. 2019;3(22):3626–34.
doi: 10.1182/bloodadvances.2019000934 pubmed: 31751471 pmcid: 6880900
Aronson J. Rare diseases, orphan drugs, and orphan diseases. BMJ. 2006;333(7559):127.
doi: 10.1136/bmj.333.7559.127 pmcid: 1502161
Chandra G. ML_GvHD: Machine Learning Models for Predicting Graft-versus-Host Disease. https://github.com/gunjanchandra280395/ML_GvHD . Accessed 12 Apr 2024.
CIBMTR. CIBMTR - Center for International Blood and Marrow Transplant Research. 2023. https://cibmtr.org . Accessed 26 Sept 2023.
Cooper JP, Perkins JD, Warner PR, Shingina A, Biggins SW, Abkowitz JL, et al. Acute Graft-Versus-Host Disease After Orthotopic Liver Transplantation: Predicting This Rare Complication Using Machine Learning. Liver Transplant. 2022;28(3):407–21.
doi: 10.1002/lt.26318
Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med. 2006;354(17):1813–26.
doi: 10.1056/NEJMra052638 pubmed: 16641398
Esteva A, Kuprel B, Novoa RA, Ko J, Swetter SM, Blau HM, et al. Dermatologist-level classification of skin cancer with deep neural networks. Nature. 2017;542(7639):115–8.
doi: 10.1038/nature21056 pubmed: 28117445 pmcid: 8382232
Glucksberg H, Storb R, Fefer A, Buckner C, Neiman P, Clift R, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from hl-a-matched sibling donor, s. Transplantation. 1974;18(4):295–304.
doi: 10.1097/00007890-197410000-00001 pubmed: 4153799
Holtan SG, Shabaneh A, Betts BC, Rashidi A, MacMillan ML, Ustun C, et al. Stress responses, M2 macrophages, and a distinct microbial signature in fatal intestinal acute graft-versus-host disease. JCI Insight. 2019;4(17):e129762.
Jagasia M, Arora M, Flowers ME, Chao NJ, McCarthy PL, Cutler CS, et al. Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood J Am Soc Hematol. 2012;119(1):296–307.
Lee J, Liu C, Kim J, Chen Z, Sun Y, Rogers JR, et al. Deep learning for rare disease: A scoping review. J Biomed Inform. 2022;104227.
Levine JE, Logan BR, Wu J, Alousi AM, Bolaños-Meade J, Ferrara JL, et al. Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: a Blood and Marrow Transplant Clinical Trials Network study. Blood J Am Soc Hematol. 2012;119(16):3854–60.
Murthy HS, Ahn KW, Estrada-Merly N, Alkhateeb HB, Bal S, Kharfan-Dabaja MA, et al. Outcomes of allogeneic hematopoietic cell transplantation in T cell prolymphocytic leukemia: a contemporary analysis from the center for international blood and marrow transplant research. Transplant Cell Ther. 2022;28(4):187-e1.
doi: 10.1016/j.jtct.2022.01.017 pmcid: 8977261
Obermeyer Z, Emanuel EJ. Predicting the future-big data, machine learning, and clinical medicine. N Engl J Med. 2016;375(13):1216.
doi: 10.1056/NEJMp1606181 pubmed: 27682033 pmcid: 5070532
Pedregosa F, Varoquaux G, Gramfort A, Michel V, Thirion B, Grisel O, et al. Scikit-learn: Machine Learning in Python. J Mach Learn Res. 2011;12:2825–30.
Pidala J, Vogelsang G, Martin P, Chai X, Storer B, Pavletic S, et al. Overlap subtype of chronic graft-versus-host disease is associated with an adverse prognosis, functional impairment, and inferior patient-reported outcomes: a Chronic Graft-versus-Host Disease Consortium study. Haematologica. 2012;97(3):451.
doi: 10.3324/haematol.2011.055186 pubmed: 22058206 pmcid: 3291602
Scarola SJ, Perdomo Trejo JR, Granger ME, Gerecke KM, Bardi M. Immunomodulatory effects of stress and environmental enrichment in Long-Evans rats (Rattus norvegicus). Comp Med. 2019;69(1):35–47.
doi: 10.30802/AALAS-CM-18-000025 pubmed: 30728094 pmcid: 6382044
Tang S, Chappell GT, Mazzoli A, Tewari M, Choi SW, Wiens J. Predicting acute graft-versus-host disease using machine learning and longitudinal vital sign data from electronic health records. JCO Clin Cancer Inform. 2020;4:128–35.
doi: 10.1200/CCI.19.00105 pubmed: 32083957

Auteurs

Gunjan Chandra (G)

Biomimetics and Intelligent Systems Group, University of Oulu, Pentti Kaiteran katu 1, 90570, Oulu, Finland. gunjan.chandra@oulu.fi.

Junfeng Wang (J)

Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, Netherlands.

Pekka Siirtola (P)

Biomimetics and Intelligent Systems Group, University of Oulu, Pentti Kaiteran katu 1, 90570, Oulu, Finland.

Juha Röning (J)

Biomimetics and Intelligent Systems Group, University of Oulu, Pentti Kaiteran katu 1, 90570, Oulu, Finland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH